These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32096556)

  • 1. Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis.
    Ornello R; Frattale I; Pistoia F; Sacco S; Notturno F
    Headache; 2020 Apr; 60(4):787-788. PubMed ID: 32096556
    [No Abstract]   [Full Text] [Related]  

  • 2. Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!
    Grazzi L; Rizzoli P
    Headache; 2020 Apr; 60(4):804-806. PubMed ID: 32096558
    [No Abstract]   [Full Text] [Related]  

  • 3. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
    Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
    Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing and durability of response to erenumab in patients with chronic migraine.
    Tepper SJ; Lucas S; Ashina M; Schwedt TJ; Ailani J; Scanlon J; Klatt J; Chou DE; Wang A; Paiva da Silva Lima G
    Headache; 2021 Sep; 61(8):1255-1263. PubMed ID: 34363708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
    Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eptinezumab (Vyepti) for migraine prevention.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):85-87. PubMed ID: 32555116
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
    Gladstone J; Chhibber S; Minhas J; Neish CS; Power GS; Lan Z; Rochdi D; Lanthier-Martel J; Bastien N
    Headache; 2022 Jan; 62(1):78-88. PubMed ID: 34807454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central effects of erenumab in migraine patients: An event-related functional imaging study.
    Ziegeler C; Mehnert J; Asmussen K; May A
    Neurology; 2020 Nov; 95(20):e2794-e2802. PubMed ID: 32917805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In brief: Erenumab (Aimovig) hypersensitivity.
    Med Lett Drugs Ther; 2019 Mar; 61(1568):48. PubMed ID: 31022159
    [No Abstract]   [Full Text] [Related]  

  • 10. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.
    Ohlsson L; Haanes KA; Kronvall E; Xu C; Snellman J; Edvinsson L
    Cephalalgia; 2019 Dec; 39(14):1745-1752. PubMed ID: 31366221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Responders to Treatment With Antibodies to the CGRP-Receptor May Profit From a Switch of Antibody Class.
    Ziegeler C; May A
    Headache; 2020 Feb; 60(2):469-470. PubMed ID: 31872439
    [No Abstract]   [Full Text] [Related]  

  • 12. A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
    Xu Y; Gabriel K; Wang Y; Zhou Y; Eisele O; Vutikullird A; Mikol DD; Lee E
    CNS Drugs; 2019 May; 33(5):513-522. PubMed ID: 30963506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erenumab: First Global Approval.
    Markham A
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries.
    Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJ; Dirven C; Danser AJ; Xu C; Snellman J; MaassenVanDenBrink A
    Cephalalgia; 2019 Dec; 39(14):1735-1744. PubMed ID: 31284729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
    Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
    PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG; Smith SM; Gums JG
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [No Abstract]   [Full Text] [Related]  

  • 18. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
    Brandes JL; Diener HC; Dolezil D; Freeman MC; McAllister PJ; Winner P; Klatt J; Cheng S; Zhang F; Wen S; Ritter S; Lenz RA; Mikol DD
    Cephalalgia; 2020 Jan; 40(1):28-38. PubMed ID: 31816249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).
    Garces F; Mohr C; Zhang L; Huang CS; Chen Q; King C; Xu C; Wang Z
    Cell Rep; 2020 Feb; 30(6):1714-1723.e6. PubMed ID: 32049005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular myasthenia gravis-like symptoms associated with erenumab: Case report.
    Marusic S; Andric J; Cigrovski Berkovic M
    Int J Clin Pharmacol Ther; 2023 Apr; 61(4):178-180. PubMed ID: 36633371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.